It's time for change; commentary in response to feature article by Halpin et al

It is essential that we re-examine the way new drugs for life-threatening illnesses are assessed and regulated. The time taken to approve lifesaving medicines for general use outside of clinical trials is prohibitively slow; people are needlessly dying. The bioethics community should be at the foref...

Full description

Saved in:  
Bibliographic Details
Main Author: Keane, Michael (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: BMJ Publ. 2015
In: Journal of medical ethics
Year: 2015, Volume: 41, Issue: 12, Pages: 954-955
Online Access: Volltext (JSTOR)
Volltext (lizenzpflichtig)
Volltext (lizenzpflichtig)

MARC

LEADER 00000caa a22000002 4500
001 1816152501
003 DE-627
005 20230426115834.0
007 cr uuu---uuuuu
008 220908s2015 xx |||||o 00| ||eng c
024 7 |a 10.1136/medethics-2013-102002  |2 doi 
035 |a (DE-627)1816152501 
035 |a (DE-599)KXP1816152501 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Keane, Michael  |e VerfasserIn  |4 aut 
245 1 0 |a It's time for change; commentary in response to feature article by Halpin et al 
264 1 |c 2015 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a It is essential that we re-examine the way new drugs for life-threatening illnesses are assessed and regulated. The time taken to approve lifesaving medicines for general use outside of clinical trials is prohibitively slow; people are needlessly dying. The bioethics community should be at the forefront of change. In particular, the rigid adherence to Evidence Based Medicine (EBM) has become irrational. New regulatory frameworks are being proposed, including that of adaptive licensing. Whereas the current model uses a one-point-in-time, all-or-nothing system of regulation, adaptive licensing allows for progressive access to a new drug during the approval process. Indeed this may be the first instance where the contemporary practice of EBM needs to be abandoned due to inherent inefficiencies. In response to the inefficiencies of the current system, a collaboration of stakeholders has established NEWDIGS (NEW Drug Development ParadIGmS). The Feature Article by Halpin and colleagues, on which this Commentary is based, gives a sophisticated survey of relevant bioethical issues. In addition this Commentary outlines a novel bioethical model to align with proposed new regulatory frameworks: a distributive-benefit-at-equilibrium model. 
773 0 8 |i Enthalten in  |t Journal of medical ethics  |d London : BMJ Publ., 1975  |g 41(2015), 12, Seite 954-955  |h Online-Ressource  |w (DE-627)323607802  |w (DE-600)2026397-1  |w (DE-576)260773972  |x 1473-4257  |7 nnns 
773 1 8 |g volume:41  |g year:2015  |g number:12  |g pages:954-955 
856 |3 Volltext  |u http://www.jstor.org/stable/44014271  |x JSTOR 
856 4 0 |u https://doi.org/10.1136/medethics-2013-102002  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u http://jme.bmj.com/content/41/12/954.abstract  |x Verlag  |z lizenzpflichtig  |3 Volltext 
935 |a mteo 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 4185606443 
LOK |0 003 DE-627 
LOK |0 004 1816152501 
LOK |0 005 20220908053650 
LOK |0 008 220908||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2022-08-03#C780AE8E8A997F1BF657DE830E2108C126C2EE6C 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 866   |x JSTOR#http://www.jstor.org/stable/44014271 
LOK |0 935   |a ixzs  |a ixrk  |a zota 
OAS |a 1  |b inherited from superior work 
ORI |a SA-MARC-ixtheoa001.raw 

Similar Items

more